Title
Category
Credits
Event date
Cost
Hunting for Better Outcomes: Management Options for Huntington’s Disease
  • 0.50 ACCME (All Other)
  • 0.50 ACCME (MD/DO Only)
  • 0.50 ACPE Pharmacy
  • 0.50 ANCC
$0.00
Huntington’s disease (HD) is a rare, progressive, genetic disorder resulting in a breakdown of nerve cells in the brain. Many types of clinicians are involved in the patient journey because HD affects movement, behavior, memory loss, impulse control, and the ability to do the simplest self-care activities. This multimedia activity provides the collaborative care team of neurologists, psychiatrists, and allied healthcare providers with an improved understanding of the fundamentals of HD, its chronic burden, and how to treat patients accordingly. Hunting for Better Outcomes provides HCPs with an enhanced understanding of HD and tools for improving overall patient outcomes.
Webcast: Challenging Cases in Lipid Lowering: Interpreting the Evidence to Patient Care
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed three challenging cases that illustrate practical points about the current challenges of optimizing LDL-C lowering therapy, as well as how to optimize treatment with statin and non-statin therapies. In addition, the cases serve to offer clinical pearls on how the newer therapies fit into the treatment landscape and inform patient selection. During the webcast, expert faculty engage in interactive discussions to offer additional perspectives and clinical pearls.
Virtual Symposium - Optimizing Lipid Lowering Therapy in Women: Gaps, Perspectives, and Advances
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk.
Webcast: Optimizing LDL-C Management Post-MI: Patient Case & Expert Discussions
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed challenging cases to illustrate practical points in the optimization of LDL-C therapy post-MI, including, but not limited to the points illustrated below. At the end of each case, faculty engage in discussions to offer clinical pearls and expert insights on the cases.
17th Annual Cardiometabolic Health Congress On-Demand
  • CMHC
  • 18.50 ABIM MOC and AMA PRA Category 1 Credit™
  • 18.50 ACPE Pharmacy
  • 18.50 AMA PRA Category 1 Credit™
  • 18.50 ANCC
  • 18.50 CDE
  • 18.50 Participation
$0.00
Hundreds of practitioners gathered in Boston in October 2022 for the annual conference from Cardiometabolic Health Congress (CMHC). In the past 17 years, this medical conference has grown to be the biggest and most-anticipated event in evidence-based education for the diagnosis, treatment, and management of cardiometabolic diseases and risk factors. The On-Demand program includes all recordings from the general sessions of the live meeting; CME Symposia are posted as separate activities within the CMHC Educational Platform.
A Shifting Paradigm: Translating Research into Treatment Approaches for ALS
  • 1.00 ACCME (All Other)
  • 1.00 ACCME (MD/DO Only)
  • 1.00 ACPE Pharmacy
  • 1.00 ANCC
$0.00
Many providers lack knowledge regarding amyotrophic lateral sclerosis (ALS) and may be unaware of available information. Arming providers with an expansive understanding is extremely important. This activity highlights the need for education efforts to provide healthcare providers with clinical updates and tools to ensure that their patients receive the best possible care.
Overwhelmed and Underdiagnosed: Understanding ADHD in Female Patients
  • 1.00 ACCME (All Other)
  • 1.00 ACCME (MD/DO Only)
  • 1.00 ACPE Pharmacy
  • 1.00 ANCC
$0.00
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in females. The presence of comorbid psychiatric disorders, including depression and anxiety, and obsessive compulsive disorder, may mitigate symptoms and delay diagnosis. The short-term effects of undiagnosed or undertreated ADHD in females presents a range of academic and social problems during childhood and adolescence. This course will provide participants an overview of current diagnostic practices and emerging treatment for ADHD in females.
Clinical Spotlight: Pediatric Diagnosis & Treatment for Rett Syndrome
  • TME
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Rett Syndrome is one of the most frequent causes of mental disability in females, with an estimated prevalence of 1 in 10,000 under the age of 12. It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.
A Closer Look: CDKL5 Deficiency Disorder & Rescue Treatment
  • 0.25 ACCME (All Other)
  • 0.25 ACCME (MD/DO Only)
  • 0.25 ACPE Pharmacy
  • 0.25 ANCC
$0.00
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare developmental epileptic encephalopathy caused by mutations in the CDLK5 gene. The CDKL5 gene provides instructions for making proteins essential for normal brain and neuron development. When there is a deficiency disorder, a hallmark symptom is seizures beginning at approximately 3 months of life.
Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients. 

Pages